Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone561-922-5808
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$26.43 million
Profitability
Miscellaneous
Employees48
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable
Sensus Healthcare (NASDAQ:SRTS) Frequently Asked Questions
What is Sensus Healthcare's stock symbol?
Sensus Healthcare trades on the NASDAQ under the ticker symbol "SRTS."
How were Sensus Healthcare's earnings last quarter?
Sensus Healthcare Inc (NASDAQ:SRTS) issued its quarterly earnings data on Thursday, August, 8th. The company reported $0.01 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.06. The business earned $7.48 million during the quarter, compared to analysts' expectations of $8.04 million. Sensus Healthcare had a negative return on equity of 8.82% and a negative net margin of 8.65%. View Sensus Healthcare's Earnings History.
When is Sensus Healthcare's next earnings date?
What price target have analysts set for SRTS?
7 Wall Street analysts have issued 12 month price targets for Sensus Healthcare's stock. Their forecasts range from $5.00 to $12.50. On average, they anticipate Sensus Healthcare's stock price to reach $9.50 in the next year. This suggests a possible upside of 47.7% from the stock's current price. View Analyst Price Targets for Sensus Healthcare.
What is the consensus analysts' recommendation for Sensus Healthcare?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensus Healthcare in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sensus Healthcare.
What are Wall Street analysts saying about Sensus Healthcare stock?
Here are some recent quotes from research analysts about Sensus Healthcare stock:
- 1. HC Wainwright analysts commented, "Our price target is derived from an EV-to-sales multiple of 6.0x and TTM revenue ($1.57/share). Risks include, but are not limited to: (1) failure of SRT and IORT systems to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of other potential pipeline products; and (3) potential dilution risk. Sensus Healthcare, Inc. May 13, 2019 H.C. WAINWRIGHT & CO." (5/13/2019)
- 2. Maxim Group analysts commented, "Sensus reported lower-than-expected 1Q19 revenue and a wider-than- expected GAAP EPS loss due to a delayed shipment of seven SRT-100 Vision systems to its largest customer. We are slightly reducing our estimates to reflect the miss and a lower 2019 growth rate." (5/10/2019)
- 3. Northland Securities analysts commented, "We note that we were not allowed to ask questions on the call, hence we raise several questions in this note. Company commentary does not provide the adequate picture, for the reasons mentioned underneath. Maintain UP / $5 PT." (2/15/2019)
Has Sensus Healthcare been receiving favorable news coverage?
News stories about SRTS stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sensus Healthcare earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Sensus Healthcare.
Are investors shorting Sensus Healthcare?
Sensus Healthcare saw a increase in short interest in August. As of August 31st, there was short interest totalling 109,400 shares, an increase of 13.3% from the July 31st total of 96,600 shares. Based on an average trading volume of 20,000 shares, the days-to-cover ratio is currently 5.5 days. Currently, 1.0% of the company's shares are sold short. View Sensus Healthcare's Current Options Chain.
Who are some of Sensus Healthcare's key competitors?
Some companies that are related to Sensus Healthcare include Utah Medical Products (UTMD), GenMark Diagnostics (GNMK), Alphatec (ATEC), Pulse Biosciences (PLSE), Westaim (WEDXF), Accuray (ARAY), Iradimed (IRMD), Inovio Pharmaceuticals (INO), Apyx Medical (APYX), SeaSpine (SPNE), Soliton (SOLY), Neuronetics (STIM), Cytosorbents (CTSO), Repro-Med Systems (REPR) and Vapotherm (VAPO).
What other stocks do shareholders of Sensus Healthcare own?
Who are Sensus Healthcare's key executives?
Sensus Healthcare's management team includes the folowing people:
- Mr. Joseph C. Sardano, Chairman, CEO & Pres (Age 66)
- Mr. Arthur R. Levine, Chief Financial Officer (Age 61)
- Mr. Kalman Fishman, COO & CTO (Age 48)
- Dr. Ziv Karni, Chief Scientific Officer (Age 74)
- Mr. Michael Sardano, VP, Gen. Counsel, Corp. Sec. and Director of Governance & Regulatory (Age 30)
When did Sensus Healthcare IPO?
(SRTS) raised $20 million in an initial public offering (IPO) on Wednesday, March 30th 2016. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company served as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.
Who are Sensus Healthcare's major shareholders?
Sensus Healthcare's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Heartland Advisors Inc. (2.27%), Perritt Capital Management Inc. (1.07%), BlackRock Inc. (0.63%), Garrison Bradford & Associates Inc. (0.60%), Susquehanna International Group LLP (0.17%) and Wells Fargo & Company MN (0.03%). Company insiders that own Sensus Healthcare stock include Arthur Levine, Joseph C Sardano, Kalman Fishman, Richard Golin and Stephen Brad Cohen. View Institutional Ownership Trends for Sensus Healthcare.
Which institutional investors are selling Sensus Healthcare stock?
SRTS stock was sold by a variety of institutional investors in the last quarter, including Perritt Capital Management Inc. and Garrison Bradford & Associates Inc.. Company insiders that have sold Sensus Healthcare company stock in the last year include Kalman Fishman, Richard Golin and Stephen Brad Cohen. View Insider Buying and Selling for Sensus Healthcare.
Which institutional investors are buying Sensus Healthcare stock?
How do I buy shares of Sensus Healthcare?
Shares of SRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sensus Healthcare's stock price today?
One share of SRTS stock can currently be purchased for approximately $6.43.
How big of a company is Sensus Healthcare?
Sensus Healthcare has a market capitalization of $106.10 million and generates $26.43 million in revenue each year. The company earns $-2,020,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Sensus Healthcare employs 48 workers across the globe.View Additional Information About Sensus Healthcare.
What is Sensus Healthcare's official website?
How can I contact Sensus Healthcare?
Sensus Healthcare's mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The company can be reached via phone at 561-922-5808 or via email at [email protected]
MarketBeat Community Rating for Sensus Healthcare (NASDAQ SRTS)
MarketBeat's community ratings are surveys of what our community members think about Sensus Healthcare and other stocks. Vote "Outperform" if you believe SRTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
